rubrica

Registri

  • Emanuele Crocetti1

  1. ISPO Toscana, Firenze
Emanuele Crocetti -

  • Se sei abbonato scarica il PDF nella colonna in alto a destra
  • Se non sei abbonato ti invitiamo ad abbonarti online cliccando qui
  • Se vuoi acquistare solo questo articolo scrivi a: abbonamenti@inferenze.it (20 euro)


Ricerca bibliografica periodo 15 ottobre 2010 – 15 gennaio 2011

Per leggere le caratteristiche di questa ROUTINE di ricerca clicca qui

Database: Pubmed/MEDline
Stringa: (("registries"[MeSH Terms] OR "registries"[All Fields] OR "registry"[All Fields]) OR ("registries"[MeSH Terms] OR "registries"[All Fields])) AND (("italy"[MeSH Terms] OR "italy"[All Fields]) OR italian[All Fields]) AND "humans"[MeSH Terms] AND ("2010/10/15"[PDat] : "2011/01/15"[PDat])

Di ogni articolo è disponibile l'abstract. Per visualizzarlo basta cliccare sul titolo.

1. Crocetti E, Buzzoni C, Zappa M. Clinical and Descriptive Epidemiology Unit, Institute for Cancer Study and Prevention ISPO, Florence, Italy. e.crocetti@ispo.toscana.it Colorectal cancer incidence rates have decreased in central Italy. Eur J Cancer Prev. 2010 Nov;19(6):424-5.
Abstract
We analyzed colorectal cancer incidence data from the Tuscany Cancer Registry, central Italy, for the period 1985-2005. We carried out a trend analysis through a Joinpoint regression analysis, and summarized trends as annual percent change (APC) of the standardized (European standard) rates. Colorectal incidence rates increased until 1996 (APC=+1.4, 95% CI: 0.8-1.9), then decreased significantly (APC=-1.1, 95% CI: -0.8 to -0.4). The change was detected as statistically significant in the age group of 54+ years. Among younger individuals, we observed an increasing incidence until 2003. In the same geographical area, a colorectal screening programme has been active from 1982; it was initially based on guaiac faecal occult blood testing (GFOBT) and on immunological testing (IFOBT) since the mid 1990s. The decline in colorectal cancer incidence since 1996, in the whole population and especially among individuals older than 54 years, may suggest the effect of FOBT screening in terms of precancerous polyps removal. PMID: 20823778 [PubMed - indexed for MEDLINE]

Breve commento a cura di Emanuele Crocetti
Si segnala una flessione dell’incidenza del tumore del coloretto in una area italiana dove l’attività di screening per il tumore del colon retto basata sulla ricerca del sangue occulto nelle feci è iniziata nei primi anni ’80. La flessione dell’incidenza riguarda specialmente l’età oggetto dello screening. Questa osservazione contrasta con l’andamento dell’incidenza osservato in Italia che è ancora generalmente in crescita mentre si allinea con quanto osservato negli USA, in Canada e in Nuova Zelanda dove la flessione dell’incidenza è attribuita alla larga diffusione della diagnostica endoscopica colorettale.

2. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hémon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjønneland A, Rodriguez L, Sánchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, González CA, Berrino F. Department of Community Medicine, University of Tromsø, Tromsø, Norway. kjersti.bakken@uit.no Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011 Jan 1;128(1):144-56. doi: 10.1002/ijc.25314.
Abstract
Menopausal hormone therapy (MHT) is characterized by use of different constituents, regimens and routes of administration. We investigated the association between the use of different types of MHT and breast cancer risk in the EPIC cohort study. The analysis is based on data from 133,744 postmenopausal women. Approximately 133,744 postmenopausal women contributed to this analysis. Information on MHT was derived from country-specific self-administered questionnaires with a single baseline assessment. Incident breast cancers were identified through population cancer registries or by active follow-up (mean: 8.6 yr). Overall relative risks (RR) and 95% confidence interval (CI) were derived from country-specific Cox proportional hazard models estimates. A total of 4312 primary breast cancers were diagnosed during 1,153,747 person-years of follow-up. Compared with MHT never users, breast cancer risk was higher among current users of estrogen only (RR: 1.42, 95% CI 1.23-1.64) and higher still among current users of combined MHT (RR: 1.77, 95% CI 1.40-2.24; p = 0.02 for combined vs. estrogen-only). Continuous combined regimens conferred a 43% (95% CI: 19-72%) greater risk compared with sequential regimens. There was no significant difference between progesterone and testosterone derivatives in sequential regimens. There was no significant variation in risk linked to the estrogenic component of MHT, neither for oral vs. cutaneous administration nor for estradiol compounds vs. conjugated equine estrogens. Estrogen-only and combined MHT uses were associated with increased breast cancer risk. Continuous combined preparations were associated with the highest risk. Further studies are needed to disentangle the effects of the regimen and the progestin component. PMID: 20232395 [PubMed - indexed for MEDLINE]

Breve commento a cura di Emanuele Crocetti
Il progetto collaborativo europeo EPIC (European Prospective Investigation into Cancer and nutrition) affronta in questo studio la relazione fra terapia ormonale sostitutiva (TOS) e rischio di tumore della mammella femminile. L’ampia coorte analizzata comprende donne in postmenopausa di Danimarca, Francia, Germania, Italia, Norvegia, Spagna, Olanda e Regno Unito, paesi nei quali l’uso della TOS al momento dell’arruolamento nella coorte varia molto per prevalenza, tipologia, modalità d’uso e via di somministrazione. Nel complesso viene confermato un incremento del rischio nelle utilizzatrici rispetto alle non utilizzatrici sia di estrogeni che di composti estro progestinici. Il rischio risulta più elevato nei regimi di assunzione continua rispetto a quelli ciclici.

3. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti, Mannucci PM, Peyvandi F. Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Luigi Villa Foundation, epartment of Medicine and Medical Specialities, Università degli Studi di Milano, Milan, Italy. Different clinical severity of first episodes and recurrences of thrombotic hrombocytopenic purpura. Br J Haematol. 2010 Dec;151(5):488-94. doi: 10.1111/j.1365-2141.2010.08385.x. pub 2010 Oct 19.
Abstract
The clinical course of thrombotic thrombocytopenic purpura (TTP) is characterized by recurrent disease episodes in up to 50% of cases. The clinical presentation and severity of different TTP episodes have not been systematically compared. Laboratory and clinical information from 51 patients with recurrent disease, derived from 136 patients with TTP included in the Milan TTP registry (URL: http://www.ttpdatabase.org), were used to compare mortality, symptoms and disease-related laboratory measurements in different disease episodes. The prevalence of severe neurological symptoms (coma, seizures, and focal neurological defects) was significantly lower in recurrences than in the first episode. Platelet counts and haemoglobin levels at presentation were higher in recurrences than in the first disease episode, and lactate dehydrogenase levels were lower. Also, mortality tended to be lower in the second and third disease episodes than in the first. Recurrences of TTP are generally milder than first episodes. These differences in severity should be taken into account in clinical research on TTP and in patient management. PMID: 20955397 [PubMed - indexed for MEDLINE]
4. Fedeli U, Alba N, Lisiero M, Zambon F, Avossa F, Spolaore P. Epidemiological Department, Veneto Region, Castelfranco Veneto, Italy. Obstetric hospitalizations among Italian women, regular and irregular immigrants in North-Eastern Italy. Acta Obstet Gynecol Scand. 2010 Nov;89(11):1432-7.
Abstract
OBJECTIVE: Italy has become an important host country for economic immigrants. The study is aimed at providing a descriptive analysis of obstetric hospitalizations among Italian and immigrant women in North-Eastern Italy.
DESIGN
: Population-based registry descriptive study.
SETTING: Veneto Region, Italy.
METHODS: All obstetric hospitalizations in 2006-2007 were extracted from the regional archive of hospital discharge records (n = 144,698). Discharges for vaginal delivery, cesarean section, threatened abortion and other antepartum diagnoses, miscarriages, and induced abortions were identified among residents with Italian or foreign citizenship, and irregular immigrants. Hospitalization rates for the above diagnostic categories were computed for Italian and foreign Veneto residents.
MAIN OUTCOME MEASURES
: Delivery rates, proportion of cesarean sections, hospitalization rates for antepartum hospitalizations, miscarriage, induced abortion, and hospitalization rate ratios of immigrants versus Italian women. RESULTS: Among Italian women, regular and irregular immigrants, the percentages of teenage deliveries were 0.7, 2.9, and 8.4%; the ratios of miscarriages to deliveries were 0.16, 0.15 and 0.35; the ratios of induced abortions to deliveries were 0.13, 0.24 and 0.81, respectively. Regular immigrants accounted for 10% of population aged 15-49 and for 20% of deliveries. The age-related increase in miscarriage risk was steeper among regular immigrants. The induced abortions to deliveries ratio peaked among Italians aged <25 and regular immigrants aged ≥35 years. 40% of Italians and 30% of regular immigrants sought care outside nearest hospitals.
CONCLUSIONS: Wide differences in reproductive behavior, health status, and patterns in the access to health services exist between Italians, regular and irregular immigrants even though they represent three connected populations. PMID: 20955097 [PubMed - indexed for MEDLINE]
5. Russo R, Esposito MR, Asci R, Gambale A, Perrotta S, Ramenghi U, Forni GL, Uygun V, Delaunay J, Iolascon A. CEINGE Biotecnologie Avanzate, Napoli, Italy. Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol. 2010 Dec;85(12):915-20. Comment in: Am J Hematol. 2010 Dec;85(12):913-4.
Abstract
SEC23B gene encodes an essential component of the coat protein complex II (COPII)-coated vesicles. Mutations in this gene cause the vast majority the congenital dyserythropoietic anemia Type II (CDA II), a rare disorder resulting from impaired erythropoiesis. Here, we investigated 28 CDA II patients from 21 unrelated families enrolled in the CDA II International Registry. Overall, we found 19 novel variants [c.2270 A>C p.H757P; c.2149-2 A>G; c.1109+1 G>A; c.387(delG) p.L129LfsX26; c.1858 A>G p.M620V; c.1832 G>C p.R611P; c.1735 T>A p.Y579N; c.1254 T>G p.I418M; c.1015 C>T p.R339X; c.1603 C>T p.R535X; c.1654 C>T p.L552F; c.1307 C>T p.S436L; c.279+3 A>G; c. 2150(delC) p.A717VfsX7; c.1733 T>C p.L578P; c.1109+5 G>A; c.221+31 A>G; c.367 C>T p.R123X; c.1857_1859delCAT; p.I619del] in the homozygous or the compound heterozygous state. Homozygosity or compound heterozygosity for two nonsense mutations was never found. In four cases the sequencing analysis has failed to find two mutations. To discuss the putative functional consequences of missense mutations, computational analysis and sequence alignment were performed. Our data underscore the high allelic heterogeneity of CDA II, as the most of SEC23B variations are inherited as private mutations. In this mutation update, we also provided a tool to improve and facilitate the molecular diagnosis of CDA II by defining the frequency of mutations in each exon. PMCID: PMC3015065 PMID: 20941788 [PubMed - indexed for MEDLINE]
6. Rebora P, Czene K, Antolini L, Passerini CG, Reilly M, Valsecchi MG. Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine and Prevention, University of Milano–Bicocca, Monza, Italy. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol. 2010 Nov 1;172(9):1028-33. Epub 2010 Sep 22.
Abstract
The authors used cancer registry data to assess the incidence rate of second primary cancers among chronic myeloid leukemia (CML) patients and the long-term survival of CML patients before the introduction of tyrosine kinase inhibitors. In the Swedish Cancer Registry, the authors identified 2,753 adult CML patients diagnosed between 1970 and 1995 who were followed through December 2007. Standardized incidence ratios (SIRs) and relative survival ratios were computed. With a total of 145 subsequent primary malignancies, an increased incidence rate of second malignancy was found for stomach cancer (SIR = 2.76, 95% confidence interval (CI): 1.33, 5.08), skin cancer (SIR = 5.36, 95% CI: 3.18, 8.47), urogenital tract cancer (SIR = 1.61, 95% CI: 1.15, 2.21), and lymphoid leukemia (SIR = 5.53, 95% CI: 1.79, 12.89). Long-term relative survival figures showed that CML was related, in the era prior to the introduction of imatinib, to a very steep decline in survival (2 years from diagnosis, relative survival = 51%, 95% CI: 49, 53). This was in spite of a marginal improvement after 1985, possibly related to the introduction of interferon-α for treatment. These estimates constitute a relevant reference for future studies and a benchmark for comparisons with prognosis in CML patients after chronic use of tyrosine kinase inhibitors. PMID: 20861143 [PubMed - indexed for MEDLINE]
7. Camilloni L, Rossi PG, Farchi S, Chini F, Borgia P, Guasticchi G. Public Health Agency of Lazio Region. Via di Santa Costanza, 53, 00198 Rome, Italy. camilloni@asplazio.it Triage and Injury Severity Scores as predictors of mortality and hospital admission for injuries: a validation study. Accid Anal Prev. 2010 Nov;42(6):1958-65. Epub 2010 Jul 2.
Abstract
BACKGROUND: Many emergency departments use a rating system to establish priority based on urgency: "triage". The aim of this study was to evaluate the validity of triage in predicting hospitalization and mortality compared to that of the ICD-9-CM based Injury Severity Score (ISS).
METHODS
: Sources: The Emergency Information System 2000, the Hospital Information System 2000-2001 and the Mortality Register 2000-2001, of the Lazio Region. Case selection: Emergency department visits for traumas that occurred on the road or at home. Outcomes: Hospitalization and 30-day mortality. For each case, trauma diagnoses from the ICD-9-CM were given a corresponding ISS value. We performed logistic models, including age, sex and, alternatively, triage or ISS. We compared discrimination measures and calibration of the models.
RESULTS
: Out of 264,709 emergency department visits, 22,249 (8.4%) were followed by a hospitalization and 655 (0.2%) died within 30 days. ISS scores were calculated for 72,179 (27%) cases. Of the most urgent triage (840 patients), 78.3% (658) were hospitalized and 9% (76) died, while among patients with ISS > or = 16 value (1276) 36.4% (464) of were hospitalized and 1.8% (23) died. Measures of discrimination and calibration showed similar results. The triage model had a better fitness in predicting hospitalization probability for home accidents (Hosmer-Lemeshow statistic: chi(2)(triage)=5.5 vs chi(2)(ISS)=34.3) and had a better performance for road accidents (ROC(triage)=0.71 vs ROC(ISS)=0.66). There were no differences between the models in predicting the probability of death.
CONCLUSIONS
: The agreement between the two scales confirms the validity of triage as a clinical management tool in the emergency department, and as a proxy of trauma severity. PMID: 20728648 [PubMed - indexed for MEDLINE]
8. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11;116(19):3724-34. Epub 2010 Jul 27.
Collaborators: Hackl M, Hackl J, Maynadie M, Holleczek B, Tryggvadottir L, Comber H, Bellu F, Giacomin A, Ferretti S, Crocetti E, Serraino D, Vercelli M, Federico M, Fusco R, Michiara M, Tumino R, Mangone L, Falcini F, Iannelli A, Budroni M, Zanetti R, Piffer S, La Rosa F, Zambon P, Sant M, Allemani C, Berrino F, Sowe S, Tereanu C, Capocaccia R, De Angelis R, Simonetti A, England K, Langmark F, Rachtan J, Mezyk R, Zwierko M, Ondrusova M, Primic-Žakelj M, Marcos-Gragera R, Khan S, Jundt G, Usel M, Ess SM, Bordoni A, Visser O, Otter R, Coebergh JW, Siesling S, Greenberg D, Easey N, Roche M, Lawrence G, Gavin A, Brewster DH, Steward J. Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. milena.sant@istitutotumori.mi.it
Abstract
Changing definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66,371 lymphoid malignancies (LMs) and 21,796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100,000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukemia (3.79), diffuse B-cell lymphoma (3.13), and Hodgkin lymphoma (2.41). The commonest MMs were acute myeloid leukemia (2.96), other myeloproliferative neoplasms (1.76), and myelodysplastic syndrome (1.24). Unknown morphology LMs were commonest in Northern Europe (7.53); unknown morphology MMs were commonest in Southern Europe (0.73). Overall incidence was lowest in Eastern Europe and lower in women than in men. For most LMs, incidence was highest in Southern Europe; for MMs incidence was highest in the United Kingdom and Ireland. Differences in diagnostic and registration criteria are an important cause of incidence variation; however, different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement. PMID: 20664057 [PubMed - indexed for MEDLINE]